Table 1.
Patients' demographic, clinical, and molecular characteristics of patient population by group.
| Summary of characteristics | |||
|---|---|---|---|
| Short term survival (n = 35) | Long term survival (n = 29) | P-value | |
| Age in years (range) | 62.6 ± 11.6 (27–83) | 58.5 ± 9.1 (41–79) | 0.114 |
| Sex | |||
| Male | 21 (60.0%) | 24 (82.8%) | 0.058 |
| Female | 14 (40.0%) | 5 (17.2%) | |
| CE volume (cm3) | 37.6 ± 28.7 | 22.9 ± 28.7 | 0.004 |
| FLAIR volume (cm3) | 109.4 ± 67.6 | 83.4 ± 76.5 | 0.074 |
| KPS, n (%) | |||
| >70% | 6 (21.4%) | 13 (52.0%) | 0.025 |
| Missing | 7 | 4 | |
| Extent of resection | |||
| Gross-total | 11 (31.4%) | 10 (34.5%) | |
| Subtotal | 13 (37.1%) | 14 (48.3%) | |
| Laser | 7 (20.0%) | 1 (3.5%) | |
| Biopsy | 4 (11.4%) | 4 (13.8%) | |
| MGMT status | |||
| Methylated | 12 (37.5%) | 13 (52.0%) | 0.297 |
| Non-methylated | 20 (62.5%) | 12 (48.0%) | |
| Missing | 3 | 4 | |
| IDH mutation | |||
| Mutated | 0 | 0 | |
| Wild type | 34 | 29 | |
| Missing | 1 | 0 | |
| EGFR amplification | |||
| Positive | 6 (30.0%) | 12 (63.2%) | 0.056 |
| Negative | 14 (70.0%) | 7 (36.8%) | |
| Missing | 15 | 10 | |
| Overall survival in days | 242.1 ± 118.0 | 840.9 ± 372.6 | <0.00001 |
STS, short-term survival (<14.6 months); LTS, long-term survival (≥14.6 months); CE, contrast enhancement; FLAIR, fluid-attenuated inversion recovery; KPS, Karnofsky performance status; MGMT, methylguanine methyltransferase; IDH, isocitrate dehydrogenase; EGFR, epidermal growth factor receptor.